CAC
AGIO icon

Cowen and Company’s Agios Pharmaceuticals AGIO Stock Holding History

Cowen and Company’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-27,132
Closed -$602K – 661
2022
Q2 		$602K Buy
27,132
+6,382
+31% +$144K 0.06% 122
2022
Q1 		$604K Buy
+20,750
New +$634K 0.06% 137
2021
Q3 		– Sell
-3,651
Closed -$201K – 577
2021
Q2 		$201K Buy
+3,651
New +$204K 0.01% 281
2019
Q4 		– Sell
-27,852
Closed -$1.05M – 451
2019
Q3 		$902K Buy
+27,852
New +$1.15M 0.23% 76

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cowen and Company's AGIO Position: Q3 2022 in Review

Cowen and Company sold out of Agios Pharmaceuticals (AGIO) in Q3 2022, closing a stake of 27,132 shares — an estimated $602K sold.

Cowen and Company first reported a position in AGIO in Q3 2019 and held it in 4 quarters. The position peaked at $902K in Q3 2019. 168 funds tracked by Wall St. Rank hold AGIO as of Q3 2022.

  • Cowen and Company reported no remaining Agios Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cowen and Company sold 27,132 Agios Pharmaceuticals shares in Q3 2022, an estimated $602K.
  • Cowen and Company first reported a position in Agios Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Cowen and Company's Agios Pharmaceuticals position peaked at $902K in Q3 2019.
  • 168 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2022.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.